Latest news with #Therapeutic
Yahoo
26-05-2025
- Business
- Yahoo
Digital Therapeutics & Medical Devices Market to Reach USD 56.76 Billion by 2034, Growing at 21.65% CAGR
Digital Therapeutics & Medical Devices Market Overview And Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, May 26, 2025 (GLOBE NEWSWIRE) -- Market Overview Digital Therapeutics & Medical Devices Market Size and Growth The global Digital Therapeutics & Medical Devices Market was valued at USD 7.88 billion in 2024 and is projected to reach USD 56.76 billion by 2034, growing at a CAGR of 21.65% during the forecast period. Get a Sample PDF Brochure: Digital Therapeutic Devices Market Insights The digital therapeutic devices segment is also witnessing robust growth, with the market expected to expand from USD 4.86 billion in 2024 to USD 14.0 billion by 2035. The Digital Therapeutics (DTx) market refers to the use of software-based interventions to prevent, manage, or treat medical disorders or diseases. These solutions are evidence-based, often prescribed by healthcare professionals, and delivered through apps, wearables, or connected platforms. DTx is distinct from general wellness apps due to its clinical validation and regulatory oversight. The Medical Devices market includes all instruments, machines, implants, and software that are used for medical purposes, such as diagnosis, treatment, and patient monitoring. When merged with digital therapeutics, it creates a powerful ecosystem combining hardware, data analytics, AI, and user-centric care delivery. Regional AnalysisNorth America Market Share: Held the largest share at 43.91% in 2024, attributed to advanced healthcare infrastructure and supportive regulatory policies. Europe Market Dynamics: Countries like Germany, the UK, and France are leading due to robust healthcare systems and government initiatives promoting digital healthcare solutions. Asia-Pacific Growth Potential: Expected to witness the fastest growth, driven by increasing healthcare digitization and a rising prevalence of chronic diseases. Browse full Report - Key Therapeutic AreasDiabetes Management Market Share: Dominated the digital therapeutics market with a 29.75% revenue share in 2024. Mental Health Market Value: Valued at USD 1.5 billion in 2024, reflecting growing awareness and demand for digital interventions in mental health. Cardiovascular Diseases Market Value: Estimated at USD 1.0 billion in 2024, with digital solutions aiding in managing heart-related ailments. Key Market Players Digital Therapeutics Companies (2025) No. Company Name Headquarters Focus Areas 1 Omada Health USA Chronic disease management, AI-driven nutrition 2 Hinge Health USA Musculoskeletal care, AI-powered physical therapy 3 Sword Health Portugal Virtual physical therapy, AI integration 4 Click Therapeutics USA Prescription digital therapeutics for mental health 5 Kaia Health Germany AI-driven chronic pain management 6 DarioHealth USA Diabetes, hypertension, weight management 7 Virta Health USA Type 2 diabetes reversal 8 Pear Therapeutics USA Digital treatments for addiction and mental health 9 Big Health USA Mental health solutions, including insomnia and anxiety 10 Teladoc Health USA Telemedicine, chronic condition management 11 Lark Health USA AI-based chronic disease management 12 Maven Clinic USA Women's and family health 13 Talkspace USA Online therapy and mental health services 14 CureApp, Inc. Japan Mobile applications for chronic disease management 15 GAIA AG Germany Evidence-based therapeutic apps 16 Welldoc, Inc. USA Diabetes management through digital platforms 17 2Morrow Inc. USA Smoking cessation and weight management 18 Reperio Health USA At-home health assessments 19 Thirty Madison USA Specialized virtual care for chronic conditions 20 Meru Health USA Digital mental health programs Buy Now : Medical Device Companies (2025) No. Company Name Headquarters Specialization 1 Medtronic Ireland Cardiovascular, diabetes, surgical devices 2 Johnson & Johnson USA Surgical instruments, implants, diagnostics 3 Abbott Laboratories USA Diabetes care, diagnostics, vascular devices 4 Siemens Healthineers Germany Imaging systems, laboratory diagnostics 5 GE Healthcare USA Imaging systems, medical devices, IT solutions 6 Philips Healthcare Netherlands Imaging systems, patient monitoring 7 Stryker Corporation USA Orthopedics, neurotechnology, surgical equipment 8 Boston Scientific USA Interventional cardiology, neuromodulation 9 Becton Dickinson (BD) USA Medical diagnostics, IV sets, syringes 10 Danaher Corporation USA Diagnostics, life sciences, dental equipment Recent Developments 1. Hinge Health's Successful IPO and AI Integration In May 2025, Hinge Health, a digital physical therapy company, went public with a strong debut, reaching a $2.6 billion valuation. The company reported an 81% gross margin and $17.1 million profit in Q1 2025. Hinge Health utilizes AI-powered tools for motion tracking and care coordination, significantly reducing clinician hours and enhancing care delivery. The company plans to expand into additional healthcare specialties, further automating care with technology. 2. Medtronic's Diabetes Division Spin-Off Medtronic announced plans to spin off its diabetes division into a standalone company. The new entity will be led by Que Dallara, current head of the diabetes division, and will employ around 8,000 people. This move aims to allow Medtronic to concentrate on its more lucrative businesses, especially heart devices. The separation is expected to be completed within 18 months. 3. Siemens Healthineers Faces Tariff Challenges Siemens Healthineers' photon-counting CT scanner, the Naeotom Alpha, has gained global acclaim, including FDA approval. However, new U.S.-EU tariffs threaten to raise costs across the supply chain, affecting both foreign and domestic manufacturers. Industry leaders warn that these tariffs could raise healthcare costs, disrupt maintenance and supply, and stifle innovation. 4. FDA Approval of Intuitive Surgical's da Vinci 5 System Intuitive Surgical received FDA clearance for its da Vinci 5 surgical system, which can be used in most surgical specialties, excluding cardiac and pediatric indications. This system, expected to enter full market launch in 2025, brings new capabilities of visualization, precision, and efficiency to operating rooms. The surgical robotics market is valued at over $8 billion in 2025 and is growing at a double-digit rate. 5. Empatica's Advancements in Wearable Health Monitoring Empatica, a company specializing in AI-enabled tools for health monitoring, has developed medical-grade wearables like Embrace2 and EmbracePlus. These devices track physiological signals such as heart rate variability and skin temperature. Embrace2 has been cleared by the FDA as a seizure alerting solution for epilepsy patients. EmbracePlus is used for continuous health monitoring and has received the European CE mark as a Class IIa medical device. 6. Samsung's Noninvasive Glucose Monitoring Technology Samsung has been developing noninvasive glucose monitoring technology using Raman spectroscopy. The company announced plans to incorporate glucose monitoring into its smartwatch, with a targeted release year of 2025. This technology aims to provide continuous glucose monitoring without the need for invasive procedures. Technological Advancements Artificial Intelligence (AI): AI integration is enhancing personalization in digital therapeutics, enabling real-time feedback and tailored treatment plans. Wearable Devices: The proliferation of wearable health devices is facilitating continuous monitoring and data collection, improving patient engagement and outcomes. Market SegmentationBy Product Type Software/Platforms: Expected to hold the largest market share due to increasing reliance on sophisticated solutions for therapeutic interventions. Devices: Includes wearable and non-wearable devices aiding in monitoring and treatment. By Sales Channel Business-to-Business (B2B): Dominated the market with a 64.51% share in 2024, driven by adoption among healthcare providers and employers. Business-to-Consumer (B2C): Growing segment with direct-to-consumer apps and platforms. This report is also available in the following languages : Japanese (片頭痛市場向けデジタル治療・医療機器), Korean (편두통 시장을 위한 디지털 치료제 및 의료 기기), Chinese (偏头痛市场的数字治疗和医疗设备), French (Thérapies numériques et dispositifs médicaux pour le marché de la migraine), German (Digitale Therapeutika und medizinische Geräte für den Migränemarkt), and Italian (Dispositivi medici e terapeutici digitali per il mercato dell'emicrania), etc. Get a Sample PDF Brochure: More Related Reports: Dyschromia Therapeutics Market The global dyschromia therapeutics market, valued at approximately $3.2 billion in 2024, is projected to reach around $5.3 billion by 2034. This represents a compound annual growth rate (CAGR) of about 5.3% during the forecast period from 2025 to 2034. Alzheimer Therapeutics Market The Alzheimer therapeutics market is valued at approximately $10 billion, reflecting a robust demand for innovative treatments in a rapidly aging population. The projected market value is anticipated to reach around $25 billion by 2034, driven by increasing prevalence rates and advancements in drug development. This results in a Compound Annual Growth Rate (CAGR) of approximately 9.5% during the forecast period of 2025-2034. Digital Therapeutics Market The global digital therapeutics market is valued at approximately $6.9 billion in 2024, with projections estimating growth to about $17.6 billion by 2034. This translates to a robust compound annual growth rate (CAGR) of around 9.7% during the forecast period from 2025 to 2034. Central Nervo System Therapeutics Market The global Central Nervous System (CNS) therapeutics market is valued at approximately $133 billion. This market is projected to reach around $194 billion by 2034, with an estimated Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period from 2025 to 2034. Acute Lymphoblastic Leukemia Therapeutics Market The global market for Acute Lymphoblastic Leukemia (ALL) therapeutics is projected to reach approximately $12 billion by 2024, driven by rising cases and advances in treatment modalities. Over the forecast period from 2025 to 2034, this market is expected to expand robustly, with a projected Compound Annual Growth Rate (CAGR) of 8.5%. This growth is fueled by innovation in targeted therapies, including monoclonal antibodies and CAR T-cell therapies, which are improving patient outcomes and survival rates. Amyloidosis Therapeutics Market The global amyloidosis therapeutics market is valued at approximately $5.3 billion in 2024, with expectations to grow significantly, reaching an estimated $10.8 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. Scleroderma Diagnostics Therapeutics Market The scleroderma diagnostics and therapeutics market is valued at approximately $1.2 billion in 2024, with projections indicating a robust growth trajectory that will elevate the market to around $2.4 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period from 2025 to 2034. U.S. Leukemia Therapeutics Market The U.S. leukemia therapeutics market is valued at approximately $22 billion, reflecting robust growth driven by advancements in precision medicine, novel drug approvals, and an increasing incidence of leukemia cases. The market is projected to reach nearly $40 billion by 2034, highlighting a significant expansion over the forecast period. Rna Based Therapeutics Market The RNA-based therapeutics market is projected to reach a value of approximately $7.3 billion in 2024, driven by advancements in mRNA technology and increasing investments in gene therapies. The market is expected to expand significantly with a projected value of around $19.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period from 2025 to 2034. U.S. Antimicrobial Therapeutics Market The U.S. antimicrobial therapeutics market is valued at approximately $70 billion in 2024, with projections suggesting it will reach around $100 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 6% over the forecast period from 2025 to 2034. U.S. Hereditary Angioedema Therapeutics Market The U.S. hereditary angioedema (HAE) therapeutics market is valued at approximately $1.6 billion in 2024, with projections estimating it will reach around $4.6 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of about 11.5% from 2025 to 2034. Antimicrobial Therapeutics Market The global antimicrobial therapeutics market is projected to reach approximately $60.5 billion in 2024, driven by increasing antibiotic resistance, rising prevalence of infectious diseases, and an expanding geriatric population. The market is poised for significant growth, with a forecasted value of around $89.2 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 4.0% during the period from 2025 to 2034. Europe Nucleic Acid Therapeutics Market The European nucleic acid therapeutics market is valued at approximately €8.5 billion, driven by advancements in mRNA technology and increasing investment in gene therapies. The growing prevalence of genetic disorders and the demand for innovative treatments present significant growth opportunities. Over the forecast period from 2025 to 2034, the market is anticipated to reach about €22 billion, reflecting a robust compound annual growth rate (CAGR) of 9.5%. U.S. Nucleic Acid Therapeutics Market The U.S. nucleic acid therapeutics market is valued at approximately $7.4 billion, driven by advancements in mRNA technologies and a surge in genetic therapies aimed at addressing unmet medical needs. The projected market value is expected to reach $18.6 billion by 2034, reflecting robust growth prospects. This translates to a compound annual growth rate (CAGR) of 9.6% during the forecast period from 2025 to 2034. Hereditary Angioedema Therapeutics Market The global market for hereditary angioedema (HAE) therapeutics is valued at approximately $3.5 billion in 2024, with projections estimating growth to around $6.2 billion by 2034. This reflects a robust compound annual growth rate (CAGR) of about 6.3% during the forecast period from 2025 to 2034. Ophthalmic Topical Therapeutics Market The ophthalmic topical therapeutics market is projected to reach a value of approximately $35 billion in 2024, driven by an increasing prevalence of ocular diseases and a growing aging population. Over the forecast period from 2025 to 2034, the market is expected to grow at a robust Compound Annual Growth Rate (CAGR) of around 6.5%, reaching an estimated value of nearly $63 billion by 2034. Protein Therapeutics Market The global protein therapeutics market is valued at approximately $276 billion in 2024, driven by increasing demand for biologics and advancements in biotechnology. The market is projected to reach around $485 billion by 2034, highlighting significant growth during the forecast period. This represents a Compound Annual Growth Rate (CAGR) of about 6.1% from 2025 to 2034. Candidiasis Therapeutics Market The global market for candidiasis therapeutics is expected to reach a value of approximately $3.2 billion in 2024, showcasing robust growth driven by increasing incidence rates of candidiasis infections, particularly among immunocompromised patients. The market is projected to expand at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2034, reaching an estimated value of around $7.5 billion by the end of the forecast period. Cancer Therapeutics Biotherapeutic Market The cancer therapeutics biotherapeutic market is valued at approximately $158 billion. This sector is anticipated to demonstrate robust growth, projecting a market value of around $284 billion by 2034, driven by advancements in personalized medicine and immunotherapy. The forecasted period from 2025 to 2034 reflects a compound annual growth rate (CAGR) of 6.2%. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
India Today
19-05-2025
- Health
- India Today
Not Ozempic, not Mounjaro. Karan Johar's weight loss secret is OMAD diet. But…
Not Ozempic, not Mounjaro — it was an OMAD diet that helped Karan Johar with his weight loss transformation. The filmmaker revealed his weight loss secret in an interview earlier this month, and since then, the term "OMAD diet" has been making a lot of buzz on the abbreviation for 'One Meal A Day', the OMAD diet is an extreme form of intermittent fasting where you consume only one meal a day. The idea is to consume the day's calorie intake in one go, within a window of an Johar revealed that the reason behind his weight loss was the discovery that he needed to correct his blood levels. Along with medication, he focused on eating one meal a day. He shared that he has been following a strict OMAD (One Meal a Day) to several lifestyle changes along with this diet, the filmmaker has not only lost a significant amount of weight but also says he is in the pink of health and has never felt this makes you want to embrace the OMAD diet right away, hold on. It might help you lose those extra kilos, but it can also cause several lifelong health OMAD DIET WORKS'The One Meal a Day (OMAD) diet is an extreme form of intermittent fasting. The idea is that the body, after receiving a large meal, enters a prolonged fasting state that potentially boosts metabolism, triggers fat burning, and lowers insulin levels, leading to weight loss,' says Dr Sharad Malhotra, Senior Consultant and Director, Gastroenterology, Hepatology and Therapeutic Endoscopy, Aakash it is just one meal, it is designed to be extremely nutritious and a Senior Dietitian at Sir Ganga Ram Hospital in Delhi, explains that an OMAD-diet meal is high in protein, includes healthy fats, provides complex carbohydrates, and is also rich in meat, tofu or legumesAvocado, nuts for healthy fatsQuinoa or brown rice for complex carbsVegetables and fruits for fibreThe portion size is larger than a regular meal typically consumed in a day. Additionally, this OMAD diet meal does not include processed foods. In the OMAD diet, the meal you eat is rich in protein and fibre. It also contains healthy fats and complex carbs. (Photo: Pexel) This one meal is generally recommended to be consumed between 4 pm and 7 pm. Ultimately, it is the doctor, along with the dietitian, who tailors the plan according to a person's routine and for water, it can be consumed throughout the day. Staying hydrated, after all, is important. One can also sip green tea or other herbal teas (without sugar).OMAD DIET AND WEIGHT LOSSBut does this diet actually help lose weight? The answer is yes, but not without some how this diet aids weight loss: 'The body enters a fasted state, leading to fat burning due to prolonged calorie deficit. Insulin levels drop, resulting in ketosis. The body acts as a fat-fuelled system. Portion control is enforced naturally, reducing overall calorie intake,' explains here is the catch – it is unsustainable in the long term. It can lead to muscle loss, metabolic slowdown, and nutrient CAN'T IGNORE THE RISKS'There is a risk of nutrient deficiencies (proteins, vitamins, and trace elements), muscle loss, and a decrease in metabolic rate. Continuous undernourishment can affect overall health and body function,' says Dr Malhotra.'Some people may also experience side effects like fatigue, headaches, or mood changes in the beginning. It may also affect hormones and muscle mass if followed long term without guidance,' adds Nidhi Sahai, Dietitian, Max Super Speciality Hospital, Vaishali, New GO 'OMAD' WITHOUT CONSULTING A DOCTORSince the OMAD diet is extremely restrictive and extreme in nature, it should not be done without consulting a doctor. Health experts may ask you to undergo certain blood tests and help you with a plan with health-related issues like diabetes, kidney diseases, liver function abnormalities, and heart issues should especially avoid this type of drastic diet pattern. Even pregnant or breastfeeding women should strictly avoid much-hyped 'one meal a day' diet is not a sustainable long-term solution. It requires a proper exit plan and continuous supervision by a health expert. In a nutshell, while the OMAD approach may offer rapid weight loss, it is neither balanced nor suitable for long-term Reel advertisement
Zawya
21-03-2025
- Health
- Zawya
Nations United Children's Fund (UNICEF) condemns looting of life-saving supplies for children from Al Bashair hospital in Khartoum State
UNICEF condemns in the strongest possible terms the looting of vital humanitarian supplies—intended to save the lives of malnourished children and provide critical healthcare to mothers and newborns from Al Bashair Hospital in Jabal Awlia, Khartoum. The looting, which included at least 2,200 cartons of Ready-to-Use Therapeutic Food (RUTF), has put the lives of over 2,000 children suffering from Severe Acute Malnutrition (SAM) at risk. The looting of Al Bashair Hospital, one of the last functioning medical facilities in Jabal Awlia, on the outskirts of the capital Khartoum, has compounded an already dire humanitarian catastrophe for children and families in the area. Commercial supplies and humanitarian aid have been blocked for more than three months due to ongoing conflict along key routes. The result is a severe shortage of food, medicine, and other essentials, with thousands of civilians trapped in active fighting. Over 4,000 people have already been forced to flee within Khartoum. "Stealing life-saving supplies meant for malnourished children is outrageous and a direct attack on their survival," said UNICEF Executive Director Catherine Russell. "These unconscionable acts against vulnerable children must end. All parties must adhere to international humanitarian law, protect civilians, and ensure safe and unhindered humanitarian access to those in need' Jabal Awlia is also one of 17 localities facing a risk of famine, according to the latest Integrated Food Security Phase Classification (IPC) update, making the loss of these supplies catastrophic for more than 100,000 acutely malnourished children. The looted iron and folic acid supplements were designated for 6,000 pregnant and lactating women. The stolen midwife kits and primary healthcare supplies would have supported over 132,980 mothers, newborns, and children in a region where healthcare access is extremely limited. UNICEF had managed to deliver these critical supplies on 20 December 2024, marking the first successful humanitarian shipment to Jabal Awlia in over 18 months. The loss of these supplies—coupled with the forced suspension of humanitarian operations due to worsening security conditions—is pushing children closer to catastrophe. Sudan is already facing one of the world's worst humanitarian crises. Over 24.6 million people - more than half the population - are experiencing high levels of acute food insecurity. The collapse of health services, the closure of schools for 17 million children, and record levels of child displacement have created an unprecedented emergency. UNICEF reiterates its urgent call for: Unimpeded humanitarian access to reach children and families in need. Protection of hospitals and other civilian infrastructure in line with international humanitarian law. Immediate security guarantees for frontline workers delivering life-saving aid. UNICEF remains committed to supporting children in Sudan and will continue working with partners to restore access to essential services. However, urgent funding and improved security conditions are needed to sustain operations and prevent further loss of life. Distributed by APO Group on behalf of United Nations Children's Fund (UNICEF).
Yahoo
03-03-2025
- Business
- Yahoo
USAID reinstates contracts for Georgia company that helps feed malnourished kids after Elon Musk responds to CNN reporting
The CEO of a plant in Georgia that makes a special peanut butter paste for severely malnourished children around the world told CNN Sunday that his company's contracts with the US Agency for International Development that had been abruptly canceled last week were all reinstated late Sunday night. Mark Moore, the founder MANA Nutrition, shared screenshots of the rescinded contract termination notifications with CNN. 'Thrilled,' he said in response to the news. He also told CNN that he was working to quickly start using USAID-labeled pouches in production again: 'It's a yo-yo. I just texted the factory and told them to switch back to USAID packaging as of midnight.' The development came after Elon Musk said on social media earlier on Sunday in response to CNN's previous reporting about the terminated USAID contracts that he would 'investigate' and 'fix it.' MANA's canceled contracts had been the result of the Trump administration's drastic efforts to slim down the federal government led by Musk, who leads a new government agency called the Department of Government Efficiency (DOGE). Moore's company makes a special kind of peanut butter paste – a type of RUTF ('Ready-to-Use Therapeutic Foods') – that many humanitarian aid workers are familiar with. It is fortified with milk and essential vitamins, packed with calories and sent to severely malnourished children around the world, including some countries in Africa. USAID has historically supported and funded the development and distribution of RUTF products over the years. On Wednesday afternoon, Moore got word from USAID that MANA's contracts with the agency were being canceled. CNN spoke with Moore just minutes after he said he received a series of contract termination letters from USAID. One of his first orders of business was asking his workers mid-production to immediately stop putting labels that say 'USAID' on the pouches that the peanut butter paste is squirted into. He said without contracts with the agency, he would not be allowed to distribute any products bearing the agency's name. The back-and-forth is just one of the many aftershocks of the Trump administration's rapid decimation of USAID, which has suffered more severely than almost any other agency across the government. Thousands of positions at the federal agency have been eliminated and the vast majority of its officials have been placed on leave. Contracts are being canceled left and right, leaving many in the humanitarian aid world reeling. In normal times, Moore's plant produces 10 pouches of the lifesaving paste every second. Each small bag contains 500 calories' worth of the special peanut butter — which does not require refrigeration or additional preparation. In their warehouse, Moore said last week, there were around 400,000 boxes of USAID-branded RUTF ready to be shipped out. He estimated that if USAID didn't pay MANA for those boxes, he would have at least $10 million in wasted peanut butter pouches on his hands. And that didn't include an additional $14 million in reimbursements from the federal government that he was already waiting for. Erin Boyd, a USAID nutrition adviser who was laid off from the agency in January, told CNN it was not an overstatement to say that children would die as a result of the decimation of USAID and funding for RUTF. 'Even before this happened, there wasn't enough funding to treat all the children who were presenting wasting.' Boyd said. Wasting, according to UNICEF, refers to a life-threatening form of malnutrition: 'Children with wasting are too thin and their immune systems are weak, leaving them vulnerable to developmental delays, disease and death,' the group says.
CNN
03-03-2025
- Business
- CNN
USAID reinstates contracts for Georgia company that helps feed malnourished kids after Elon Musk responds to CNN reporting
The CEO of a plant in Georgia that makes a special peanut butter paste for severely malnourished children around the world told CNN Sunday that his company's contracts with the US Agency for International Development that had been abruptly canceled last week were all reinstated late Sunday night. Mark Moore, the founder MANA Nutrition, shared screenshots of the rescinded contract termination notifications with CNN. 'Thrilled,' he said in response to the news. He also told CNN that he was working to quickly start using USAID-labeled pouches in production again: 'It's a yo-yo. I just texted the factory and told them to switch back to USAID packaging as of midnight.' The development came after Elon Musk said on social media earlier on Sunday in response to CNN's previous reporting about the terminated USAID contracts that he would 'investigate' and 'fix it.' MANA's canceled contracts had been the result of the Trump administration's drastic efforts to slim down the federal government led by Musk, who leads a new government agency called the Department of Government Efficiency (DOGE). Moore's company makes a special kind of peanut butter paste – a type of RUTF ('Ready-to-Use Therapeutic Foods') – that many humanitarian aid workers are familiar with. It is fortified with milk and essential vitamins, packed with calories and sent to severely malnourished children around the world, including some countries in Africa. USAID has historically supported and funded the development and distribution of RUTF products over the years. On Wednesday afternoon, Moore got word from USAID that MANA's contracts with the agency were being canceled. CNN spoke with Moore just minutes after he said he received a series of contract termination letters from USAID. One of his first orders of business was asking his workers mid-production to immediately stop putting labels that say 'USAID' on the pouches that the peanut butter paste is squirted into. He said without contracts with the agency, he would not be allowed to distribute any products bearing the agency's name. The back-and-forth is just one of the many aftershocks of the Trump administration's rapid decimation of USAID, which has suffered more severely than almost any other agency across the government. Thousands of positions at the federal agency have been eliminated and the vast majority of its officials have been placed on leave. Contracts are being canceled left and right, leaving many in the humanitarian aid world reeling. In normal times, Moore's plant produces 10 pouches of the lifesaving paste every second. Each small bag contains 500 calories' worth of the special peanut butter — which does not require refrigeration or additional preparation. In their warehouse, Moore said last week, there were around 400,000 boxes of USAID-branded RUTF ready to be shipped out. He estimated that if USAID didn't pay MANA for those boxes, he would have at least $10 million in wasted peanut butter pouches on his hands. And that didn't include an additional $14 million in reimbursements from the federal government that he was already waiting for. Erin Boyd, a USAID nutrition adviser who was laid off from the agency in January, told CNN it was not an overstatement to say that children would die as a result of the decimation of USAID and funding for RUTF. 'Even before this happened, there wasn't enough funding to treat all the children who were presenting wasting.' Boyd said. Wasting, according to UNICEF, refers to a life-threatening form of malnutrition: 'Children with wasting are too thin and their immune systems are weak, leaving them vulnerable to developmental delays, disease and death,' the group says.
